The therapy of lowering uric acid in patients with chronic kidney disease (Part 3)
Let us now make a review of our discussion and mention the findings of the study.
Chronic kidney disease (CKD) does affect more than 10% of the United States general population, and it is estimated that approximately 850 million people worldwide are affected by kidney diseases.
The high prevalence of CKD has prompted efforts to identify treatable risk factors of kidney disease.
Uric acid is the result of purine metabolite which may lead to impacting vascular smooth muscle cell proliferation, inhibition of nitric oxide production, endothelial dysfunction, and oxidative stress.
Too much uric acid may lead to harmful organ effects, increasing risk of ischemic stroke, myocardial infarction, and congestive heart failure in observational studies.
Additionally, high uric acid level is linked with hypertension, which may harm the kidneys.
The casual link between kidney function and uric acid level is complex, as decreased kidney function itself can result in hyperuricemia.
High urate level was also linked with a higher incidence of CKD in previously healthy individuals.
Experts found out that uric acid–lowering therapy was not associated with beneficial kidney outcomes.
Uric acid–lowering therapy was linked with a higher risk of new-onset CKD.
The existing evidence does not support the administration of uric acid–lowering therapies as a means to prevent the development of CKD.